# A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT01266811** · PHASE3 · WITHDRAWN · sponsor: **Centocor, Inc.**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Placebo, Velcade and dexamethasone
- **BIOLOGICAL:** Siltuximab, Velcade and dexamethasone

## Key facts

- **NCT ID:** NCT01266811
- **Lead sponsor:** Centocor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-07
- **Primary completion:** 2014-04
- **Final completion:** 2014-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study canceled based on results of different study with similar hypothesis, investigational agent, \& patient
- **Last updated:** 2013-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01266811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01266811, "A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01266811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*